The AEFI system relies on a structured investigation process. Once an AEFI is reported, it is categorized (minor, severe, serious). Serious cases, involving hospitalization, disability, or death, trigger immediate, thorough investigation. This involves reviewing medical history, clinical findings, and sometimes laboratory tests. Data from multiple reported AEFIs are then aggregated and analyzed to identify patterns or clusters. If a cluster of similar serious events occurs with a specific vaccine batch or type, it raises a red flag for a potential causal link. The challenge lies in attributing causality, especially for rare events or when pre-existing conditions complicate the picture. It requires robust epidemiological and clinical expertise to differentiate true vaccine effects from coincidental events.

The Centre's counsel presented data up to December 2024, stating that out of 220 crore total doses administered, 92,697 AEFI cases were reported (0.0042%), with 1,171 deaths (0.00005%). These figures categorized 89,854 as minor and 2,843 as severe/serious cases. From an exam perspective, these specific percentages (0.0042% for all AEFIs and 0.00005% for deaths) are highly testable in Prelims MCQs. They highlight the extremely low incidence of reported adverse events relative to the massive scale of vaccination, which is often used to underscore the overall safety profile of vaccines, while still acknowledging the importance of each serious case.

While AEFI is effective for detecting acute and sub-acute events, its primary limitation in addressing long-term effects is the inherent difficulty in establishing causality over extended periods. Many health conditions develop over years, making it challenging to definitively link them to a vaccine administered much earlier, especially when other lifestyle or environmental factors are at play. This gap can fuel public skepticism about new vaccines, as people worry about unknown future risks. Furthermore, maintaining public trust requires not just data collection but also clear, consistent, and empathetic communication about findings, risks, and the compensation process. Perceived delays in investigation or lack of transparent communication can erode confidence, even if the system is technically sound.

The Supreme Court's directives are pivotal. 'No-fault compensation' significantly strengthens the system by providing a streamlined, less adversarial path for victims to receive support, thereby reducing litigation burden and potentially encouraging more reporting. Public data disclosure fosters transparency, which is vital for building and maintaining public trust, especially in large-scale vaccination drives. Further reforms could include:

• •Expedited Causal Assessment: Reducing the time taken for investigation and causal assessment of serious AEFIs.
• •Enhanced Communication Strategy: Proactive and clear communication from health authorities, using simple language, to address public concerns and dispel misinformation.
• •Independent Oversight: Potentially involving independent expert bodies for periodic review of the AEFI system's functioning and causal assessment methodologies to boost credibility.
• •Proactive Surveillance for Specific Groups: Targeted monitoring for vulnerable populations or those receiving new vaccines.

The AEFI system relies on a structured investigation process. Once an AEFI is reported, it is categorized (minor, severe, serious). Serious cases, involving hospitalization, disability, or death, trigger immediate, thorough investigation. This involves reviewing medical history, clinical findings, and sometimes laboratory tests. Data from multiple reported AEFIs are then aggregated and analyzed to identify patterns or clusters. If a cluster of similar serious events occurs with a specific vaccine batch or type, it raises a red flag for a potential causal link. The challenge lies in attributing causality, especially for rare events or when pre-existing conditions complicate the picture. It requires robust epidemiological and clinical expertise to differentiate true vaccine effects from coincidental events.

The Centre's counsel presented data up to December 2024, stating that out of 220 crore total doses administered, 92,697 AEFI cases were reported (0.0042%), with 1,171 deaths (0.00005%). These figures categorized 89,854 as minor and 2,843 as severe/serious cases. From an exam perspective, these specific percentages (0.0042% for all AEFIs and 0.00005% for deaths) are highly testable in Prelims MCQs. They highlight the extremely low incidence of reported adverse events relative to the massive scale of vaccination, which is often used to underscore the overall safety profile of vaccines, while still acknowledging the importance of each serious case.

While AEFI is effective for detecting acute and sub-acute events, its primary limitation in addressing long-term effects is the inherent difficulty in establishing causality over extended periods. Many health conditions develop over years, making it challenging to definitively link them to a vaccine administered much earlier, especially when other lifestyle or environmental factors are at play. This gap can fuel public skepticism about new vaccines, as people worry about unknown future risks. Furthermore, maintaining public trust requires not just data collection but also clear, consistent, and empathetic communication about findings, risks, and the compensation process. Perceived delays in investigation or lack of transparent communication can erode confidence, even if the system is technically sound.

The Supreme Court's directives are pivotal. 'No-fault compensation' significantly strengthens the system by providing a streamlined, less adversarial path for victims to receive support, thereby reducing litigation burden and potentially encouraging more reporting. Public data disclosure fosters transparency, which is vital for building and maintaining public trust, especially in large-scale vaccination drives. Further reforms could include:

• •Expedited Causal Assessment: Reducing the time taken for investigation and causal assessment of serious AEFIs.
• •Enhanced Communication Strategy: Proactive and clear communication from health authorities, using simple language, to address public concerns and dispel misinformation.
• •Independent Oversight: Potentially involving independent expert bodies for periodic review of the AEFI system's functioning and causal assessment methodologies to boost credibility.
• •Proactive Surveillance for Specific Groups: Targeted monitoring for vulnerable populations or those receiving new vaccines.